Mizuho Securities Remains Sidelined on Allergan (AGN) following 1Q Earnings; PT to $232
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Goldman Sachs Sees Catalysts for Allergen (AGN) and Adds to Conviction Buy List
May 13, 2016 6:37 AM EDT(Updated - May 13, 2016 8:58 AM EDT)
Goldman Sachs upgraded Allergen (NYSE: AGN) from Buy to Conviction Buy, with a price target of $275, implying upside of 27%. Following management meetings, analyst Jami Rubin has increased confidence in Allergen's underlying business, and she sees sustainable topline growth with operating margin expansion.
"Our increased confidence is based on 1) a... More
Wall Street mixed as Apple tumbles to two-year low
May 12, 2016 7:42 AM EDTBy Noel Randewich
(Reuters) - U.S. stocks ended mixed on Thursday, with gains in telecommunications and consumer staples helping make up for a tumble in Apple to a two-year low.
The S&P 500 and Dow Jones swerved between gains and losses before ending virtually flat. Up 0.90 percent, Microsoft was the largest upward force in the S&P 500.
Apple Inc (NASDAQ: AAPL), a mainstay in many portfolios, was the heaviest drag on the three major indexes, slumping 2.35 percent to $90.34, its lowest since June 2014, as worries festered about... More
Allergan plc (AGN): Incrementally Cautious - Piper Jaffray
May 11, 2016 7:46 AM EDTPiper Jaffray analyst, David Amsellem, is cautious on Allergen (NYSE: AGN) despite bright spots in the quarter. The company needs incremental products to growth the top line leaving the path to growth murky.
AGN reported non-GAAP diluted EPS of $3.04 on revenues of $3.8B,... More
